Endocrine Unit, Evgenidion Hospital, University of Athens, 20 Papadiamantopoulou Street, 11528 Athens, Greece.
Med Clin North Am. 2012 Mar;96(2):269-81. doi: 10.1016/j.mcna.2012.01.012. Epub 2012 Feb 14.
Thyroid hormones regulate cholesterol and lipoprotein metabolism, whereas thyroid disorders, including overt and subclinical hypothyroidism, considerably alter lipid profile and promote cardiovascular disease. Good evidence shows that high thyroid-stimulating hormone (TSH) is associated with a nonfavorable lipid profile, although TSH has no cutoff threshold for its association with lipids. Thyromimetics represent a new class of hypolipidemic drugs: their imminent application in patients with severe dyslipidemias, combined or not with statins, will improve the lipid profile, potentially accelerate energy expenditure and, as a consequence, vitally lessen the risk of cardiovascular disease.
甲状腺激素调节胆固醇和脂蛋白代谢，而甲状腺疾病，包括显性和亚临床甲状腺功能减退症，会极大地改变血脂谱并促进心血管疾病的发生。有充分的证据表明，高促甲状腺激素（TSH）与不良的血脂谱有关，尽管 TSH 与血脂之间没有关联的截断值。甲状腺刺激素类似物是一类新的降脂药物：它们即将在严重血脂异常的患者中应用，与他汀类药物联合或不联合应用，将改善血脂谱，潜在地加速能量消耗，从而极大地降低心血管疾病的风险。
